• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by IMAC Holdings Inc.

    3/31/25 4:42:47 PM ET
    $BACK
    Medical Specialities
    Health Care
    Get the next $BACK alert in real time by email
    NT 10-K 1 formnt10-k.htm

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      SEC FILE NUMBER
    001-38797

     

      FORM 12b-25   CUSIP NUMBER
    44967K302

     

    NOTIFICATION OF LATE FILING

     

    (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K
      ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

     

      For Period Ended: December 31, 2024
      ☐ Transition Report on Form 10-K  
      ☐ Transition Report on Form 20-F  
      ☐ Transition Report on Form 11-K  
      ☐ Transition Report on Form 10-Q  
      ☐ Transition Report on Form N-SAR  
      For the Transition Period Ended:  

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.
    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
     

     

    PART I — REGISTRANT INFORMATION

     

    IMAC Holdings, Inc.
    Full Name of Registrant
     
     
    Former Name if Applicable
     
    3401 Mallory Lane, Suite 100
    Address of Principal Executive Office (Street and Number)
     
    Franklin, TN 37067
    City, State and Zip Code

     

     

     

     

     

     

    PART II — RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to

    Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

    (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
    ☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; and
         
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III — NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    IMAC Holdings, Inc. (the “Company”) is unable to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “2024 Form 10-K”) within the prescribed time period without unreasonable effort or expense because additional time is needed to prepare the financial statements for the annual period ended December 31, 2024, due to minimal staffing. The Company anticipates that it will file its 2024 Form 10-K within the fifteen-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934, as amended.

     

    PART IV — OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

      Sheri Gardzina (303) 898-5896
      (Name) (Area Code) (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).

     

    Yes ☒ No ☐

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

     

    Yes☐ No ☒

     

    If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

      IMAC Holdings, Inc.  
      (Name of Registrant as Specified in Charter)  

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date March 31, 2025 By /s/ Sheri Gardzina
          Sheri Gardzina
          Chief Financial Officer

     

    Instruction: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

     

     

     

     

    Get the next $BACK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BACK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BACK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

      Golden, CO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the presentation of new data demonstrating that MHC-II protein expression is a superior predictor of response to pembrolizumab (Keytruda®) compared to PD-L1 at the upcoming National Comprehensive Cancer Network (NCCN) Annual Conference. The study, conducted with I-SPY 2 clinical trial results, evaluated five different PD-L1 antibodies – including the one most commonly used as a companion diagnostic – yet only MHC-II expression showed a statistically significant correlation with patient outcomes. "Although PD-L1 testing is standard in some cases, many pati

      2/24/25 8:15:00 AM ET
      $BACK
      Medical Specialities
      Health Care
    • Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

      Golden, CO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), today announced the completed transfer of Proprietary Laboratory Analyses (PLA) code 0249U – originally issued to Theralink Technologies, Inc. – to Ignite Proteomics LLC. The AMA CPT code is listed on the Medicare Clinical Laboratory Fee Schedule (CLFS) and is addressed by the Palmetto GBA MolDx "Proteomics Testing" article (A59636). This milestone integrates both the laboratory capability and the owned and licensed intellectual property of the proteomic breast cancer assay into Ignite Proteomics. PLA codes like 0249U are essential building blocks for new diagnostics, as

      2/19/25 9:15:00 AM ET
      $BACK
      Medical Specialities
      Health Care
    • Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

      The new study adds to growing evidence that measuring activated proteins is key to cancer therapy selection. Golden, CO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc. (NASDAQ:BACK), announces the publication of a significant study in the British Journal of Cancer titled "Functional activation of the AKT–mTOR signalling axis in a real-world metastatic breast cancer cohort". This research underscores the critical importance of measuring functional protein activation within the AKT–mTOR signaling pathway to accurately predict patient responses to targeted cancer therapies. Advancing Precision Oncology Through Direct Protein Activation Measu

      2/10/25 9:15:00 AM ET
      $BACK
      Medical Specialities
      Health Care

    $BACK
    SEC Filings

    See more
    • IMAC Holdings Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement

      8-K - IMAC Holdings, Inc. (0001729944) (Filer)

      5/6/25 4:46:07 PM ET
      $BACK
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by IMAC Holdings Inc.

      8-K - IMAC Holdings, Inc. (0001729944) (Filer)

      5/2/25 4:36:49 PM ET
      $BACK
      Medical Specialities
      Health Care
    • IMAC Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - IMAC Holdings, Inc. (0001729944) (Filer)

      4/25/25 7:03:26 PM ET
      $BACK
      Medical Specialities
      Health Care

    $BACK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by IMAC Holdings Inc. (Amendment)

      SC 13G/A - IMAC Holdings, Inc. (0001729944) (Subject)

      2/7/23 2:03:35 PM ET
      $BACK
      Medical Specialities
      Health Care

    $BACK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

      4 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/18/25 12:01:15 PM ET
      $BACK
      Medical Specialities
      Health Care
    • Large owner Ruiz Jorge bought $590,192 worth of shares (164,872 units at $3.58) and sold $39,955 worth of shares (16,487 units at $2.42) (SEC Form 4)

      4 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/14/25 3:43:49 PM ET
      $BACK
      Medical Specialities
      Health Care

    $BACK
    Leadership Updates

    Live Leadership Updates

    See more
    • IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

      Golden, CO, July 11, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) (the "Company" or "IMAC"), a leading innovator in proteomics research and technology, announced the appointment of Dr. Peter Beitsch and Dr. Matthew Schwartz to its Board of Directors, effective June 26, 2024. This strategic move underscores the Company's commitment to advancing its position in the field of proteomics and driving innovation in precision medicine. Dr. Matthew Schwartz brings over 18 years of experience in the care of cancer patients using radiotherapy treatments and precision oncology. He currently serves as a practicing Radiation Oncologist at Comprehensive Cancer Centers of Nevada. "I am hono

      7/11/24 9:21:00 AM ET
      $BACK
      Medical Specialities
      Health Care
    • DayDayCook Names Jeffrey Ervin as Co-Chief Financial Officer

      NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- DDC Enterprise, Ltd., (NYSEAM:DDC) ("DayDayCook," "DDC," or the "Company"), a leading content-driven food consumer brand, today announced that Jeffrey Ervin, has been named Co-Chief Financial Officer, effective immediately. Mr. Ervin will initially be focused on leveraging his background in U.S. capital markets to oversee the financial controls, reporting requirements, and aid in investor engagement for DayDayCook. "Jeff's background as a public company CEO, along with his extensive experience in corporate finance, will be instrumental in establishing DayDayCook in the U.S. financial markets" said Norma Chu, DayDayCook's founder and CEO. "With o

      6/25/24 9:00:00 AM ET
      $BACK
      $DDC
      Medical Specialities
      Health Care
      Packaged Foods
      Consumer Staples
    • IMAC Holdings Announces Leadership Succession

      Faith Zaslavsky appointed as CEO to succeed Jeff Ervin FRANKLIN, Tenn., May 24, 2024 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC") today announced leadership transitions to the board of directors and executive team. Faith Zaslavsky has been appointed chief executive officer, succeeding Jeff Ervin, to lead newly acquired assets in the proteomics and precision medicine industry. "I am excited and honored to join IMAC and continue the mission that Jeff and team created, which is focused on providing better outcomes for patients," said Ms. Zaslavsky. "In the 23 years of working in the genomic space, I have never been more excited about a product and the brilliant and dynami

      5/24/24 9:00:00 AM ET
      $BACK
      Medical Specialities
      Health Care

    $BACK
    Financials

    Live finance-specific insights

    See more
    • IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business

      FRANKLIN, Tenn., May 07, 2024 (GLOBE NEWSWIRE) -- On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings, Inc. (NASDAQ:BACK) ("BACK") and Theralink Technologies, Inc. ("Theralink"), BACK acquired the assets of Theralink, other than certain excluded assets, in settlement of the default by Theralink of certain outstanding debt and BACK's agreement to issue certain shares of preferred stock of BACK to Theralink and/or certain holders of debt of Theralink, as applicable, in the future following the completion of a third party valuation of Theralink's business. With BACK already in possession of such assets of Theralink,

      5/7/24 8:30:00 AM ET
      $BACK
      Medical Specialities
      Health Care
    • IMAC Holdings Announces $4.3 Million Private Placement of Convertible Preferred Stock and Warrants Priced at the Market

      Franklin, Tennessee, July 26, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (NASDAQ:BACK) ("IMAC" or the "Company"), a provider of innovative medical advancements and care specializing in regenerative rehabilitation orthopedic treatments, announced today that it entered into a definitive securities purchase agreement with several institutional and accredited investors, including existing significant investors of Theralink Technologies, Inc., its previously announced merger partner (OTC:THER) ("Theralink"), and Theralink's Chairman, for the sale of its preferred stock and warrants. IMAC sold an aggregate of 2,500 shares of its Series A-1 Convertible Preferred Stock, stated value $1,000 per s

      7/26/23 9:25:00 AM ET
      $BACK
      Medical Specialities
      Health Care
    • IMAC Holdings, Inc announces the sale of The BackSpace

      BRENTWOOD, Tenn., March 01, 2023 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: BACK) ("IMAC" or the "Company"), announces today it has completed the sale of The BackSpace for an undisclosed price to Curis Functional Health. The BackSpace offers convenient and affordable spinal health and wellness services in select Walmart locations. "We are excited for the Curis team to support and grow the business going forward while we return our focus to non-surgical medical care for a person's optimal orthopedic function, stability, and mobility," said Jeff Ervin, Chief Executive Officer of IMAC. In addition to the sale of The BackSpace, the Company's Chief Operating Officer, Dr. Ben Lerner, ann

      3/1/23 9:30:00 AM ET
      $BACK
      Medical Specialities
      Health Care

    $BACK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 5 filed by Ruiz Jorge

      5 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/18/25 12:03:25 PM ET
      $BACK
      Medical Specialities
      Health Care
    • Large owner Ruiz Jorge bought $3 worth of shares (1 units at $2.69), increasing direct ownership by 0.00% to 141,230 units (SEC Form 4)

      4 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/18/25 12:01:15 PM ET
      $BACK
      Medical Specialities
      Health Care
    • Large owner Ruiz Jorge sold $15,000 worth of shares (5,000 units at $3.00), decreasing direct ownership by 3% to 141,229 units (SEC Form 4)

      4 - IMAC Holdings, Inc. (0001729944) (Issuer)

      3/18/25 11:59:00 AM ET
      $BACK
      Medical Specialities
      Health Care